相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN
Michelandrea De Cesare et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis
Kui Li et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia
Andrea Velardi et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
Cellular immunotherapy for ovarian cancer
Martin J. Cannon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
Mattias Carlsten et al.
JOURNAL OF IMMUNOLOGY (2009)
Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment
Amorette Barber et al.
JOURNAL OF IMMUNOLOGY (2009)
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Karl-Johan Malmberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Artificial cells for the development of cell therapy
Naoya Kobayashi
CELL TRANSPLANTATION (2008)
Immunotherapy opportunities in ovarian cancer
Christina S. Chu et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Comparison in the effects of IL-2, IL-12, IL-15 and IFNα on gene regulation of granzymes of human NK cell line NK-92
Bin Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2008)
Inhibition of human ovarian tumor growth by cytokine-induced killer cells
Hwan Mook Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2007)
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer
Arnorette Barber et al.
CANCER RESEARCH (2007)
Prospects for the use of NK cells in immunotherapy of human cancer
Hans-Gustaf Ljunggren et al.
NATURE REVIEWS IMMUNOLOGY (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Irradiated KHYG-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line
G. Suck et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2006)
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study
JK Chan et al.
CLINICAL CANCER RESEARCH (2006)
Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers
YY Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity
G Suck et al.
EXPERIMENTAL HEMATOLOGY (2005)
Ovarian carcinoma expresses the NKG2D ligand letal and promotes the survival and expansion of CD28- antitumor T cells
JR Conejo-Garcia et al.
CANCER RESEARCH (2004)
Ex vivo expansion of natural killer cells for clinical applications
HG Klingemann et al.
CYTOTHERAPY (2004)
Letal, a tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells
JR Conejo-Garcia et al.
CANCER BIOLOGY & THERAPY (2003)
Natural killer cell receptor signaling
LL Lanier
CURRENT OPINION IN IMMUNOLOGY (2003)
Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy
YK Tam et al.
CYTOTHERAPY (2003)
New aspects of natural-killer-cell surveillance and therapy of cancer
MJ Smyth et al.
NATURE REVIEWS CANCER (2002)
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
T Tonn et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation
M Yagita et al.
LEUKEMIA (2000)
Malignant hematopoietic cell lines:: in vitro models for the study of natural killer cell leukemia-lymphoma
HG Drexler et al.
LEUKEMIA (2000)
分享论文
